📅 Date: Friday, 30 OCTOBER 2026

🕰️ Time: 12:00 PM - 1:00 PM (AEDT)

📍 Location: Online (Zoom)

🎙️Topic: Increasing the uptake of guideline directed medical therapies in CKD

Chronic kidney disease (CKD) is a growing global public health challenge, with a substantial burden of cardiovascular and kidney-related morbidity. Over the past decade, new therapies have emerged that can slow CKD progression and reduce the risk of cardiovascular and kidney outcomes. However, translating evidence from clinical trials into routine clinical practice remains a challenge. This presentation will examine the key barriers and enablers to the uptake of evidence-based CKD therapies in Canada, with a particular focus on the healthcare context and clinical practice environment in the province of British Columbia. It will also discuss potential strategies to improve the implementation and equitable use of these therapies in routine care.

🗣️ Presented by: Dr Tae Won Yi (Winner of HSRAANZ’s 2024 Best Implementation Science Paper)

Dr Tae Won Yi is a nephrologist and postdoctoral fellow at the University of Toronto in the Cardiovascular, Renal, Endocrinology, and Metabolic Diseases Fellowship. He completed his internal medicine and nephrology training at the University of British Columbia in Vancouver, Canada, and earned his PhD from the University of New South Wales in Sydney, Australia. His PhD focused on improving the uptake of evidence-based therapies in CKD and diabetes. His research focuses on clinical trials and implementation science, with an emphasis on generating evidence and translating it into routine clinical practice.

Contact the host of HSRAANZ October 2026 Webinar - Increasing the uptake of guideline directed medical therapies in CKD

There were 0 errors found in the information you submitted: